MiMedx Posts Record 2025 Growth Amid Medicare Reimbursement Challenges
Event summary
- MiMedx reported 27% year-over-year net sales growth in Q4 2025, with full-year 2025 sales up 20% to $419 million.
- GAAP net income for Q4 2025 was $15 million, with adjusted EBITDA margin at 25% of net sales.
- The company announced a $100 million share repurchase program over two years.
- 2026 net sales are projected to range between $340-$360 million, with adjusted EBITDA margin in the mid-to-high teens.
- Medicare reimbursement changes are expected to disrupt short-term demand in the Wound market.
The big picture
MiMedx's strong 2025 performance highlights its leadership in wound care and surgical products, but the company faces short-term challenges from Medicare reimbursement changes. The $100 million share repurchase program signals confidence in long-term growth, despite potential disruptions in the Wound market. The healthcare sector continues to grapple with regulatory shifts, impacting medical device companies' revenue streams and strategic planning.
What we're watching
- Regulatory Headwinds
- How Medicare reimbursement changes will affect MiMedx's Wound market demand and revenue in 2026.
- Market Expansion
- Whether MiMedx can sustain growth in Surgical and international markets amid Wound market disruptions.
- Capital Allocation
- The pace at which MiMedx executes its $100 million share repurchase program and its impact on stock performance.
Our editorial coverage:
Related topics